Impact of Antihypertensive Drug Class on Outcomes in SPRINT.
Douglas D DeCarolisAmy A GravelyChristine M OlneyAreef IshaniPublished in: Hypertension (Dallas, Tex. : 1979) (2022)
The SPRINT trial demonstrated a lower target blood pressure led to reductions in adverse cardiovascular events. This analysis suggests greater exposure to thiazide-type diuretics and renin-angiotensin system blockers also contributed to reduced adverse cardiovascular events. Greater exposure to beta-blockers was associated with increased cardiovascular events.
Keyphrases
- cardiovascular events
- blood pressure
- coronary artery disease
- cardiovascular disease
- angiotensin converting enzyme
- hypertensive patients
- high intensity
- adverse drug
- resistance training
- clinical trial
- type diabetes
- phase ii
- phase iii
- randomized controlled trial
- skeletal muscle
- emergency department
- insulin resistance
- blood glucose
- electronic health record